Contract Notice Detail

Summary Information

Summary Information
541,749.22 Euro
 
ULS São José 51039924 - URGENTE 
Bleomicina 15000 U.I. pó sol inj fr IA Intralesional IM Iperitoneal IpleuraL IV, Etanercept 25 mg pó sol inj fr SC, Lenvatinib 10 mg cáps, Sunitinib 25 mg cáps e Tildracizumab 100 mg/1 ml sol inj ser  
Tendering Phase
Awarded
Aquisição de Bleomicina 15000 U.I. pó sol inj fr IA Intralesional IM Iperitoneal IpleuraL IV, Etanercept 25 mg pó sol inj fr SC, Lenvatinib 10 mg cáps, Sunitinib 25 mg cáps e Tildracizumab 100 mg/1 ml sol inj ser 1 ml SC 
VortalGOV - Acquisition under a Framework Agreement (via Direct Award) 
Lot NameLot Base PriceExpected Duration
B369 - BLEOMICINA (PÓ P/ SOL INJ) [15.000 U.I.; FRS]-146 (Days)
E199 - ETANERCEPT [25 MG/ML; 1 ML; FRS]-146 (Days)
L1066 - LENVATINIB [10 MG; CÁP/ COMP]-146 (Days)
S349 - SUNITINIB [25 MG; CÁP/COMP]-146 (Days)
T1636 - TILDRACIZUMAB [100 MG/ 1 ML; SOL INJ; SERINGA]-146 (Days)

Object of the Contract

Object of the Contract
Supplies Acquisition 
Rua José António Serrano 1150-199 Arroios Lisboa PORTUGAL  
33600000-6 - Pharmaceutical products
 
 
 

Scheduling

Scheduling
8/7/2024 8:47 AM (UTC +1 hour)
 
9/4/2023 8:36 AM (UTC +1 hour)
 
8/9/2024 2:00 PM (UTC +1 hour)
 

Financial Settings

Financial Settings
No 

Contract Documents

Contract Documents
Document NameDescriptionDoc Classification
convite 41039924.pdfconvite 41039924.pdfDownload

Object of contract

No 
No 

Legal, economic, financial and technical information

No 

Questionnaire

Questionnaire
1
Lot Title
B369 - BLEOMICINA (PÓ P/ SOL INJ) [15.000 U.I.; FRS]
Base Price
5 040,00

1.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
B369 BLEOMICINA (PÓ P/ SOL INJ) [15.000 U.I.; FRS] 250,000000 NXTWY.UMT.17649
Buyer Comment: 508622263 | Accord Healthcare, Unipessoal, Lda. | CPA:2023491/528/0543 | NºAIM:5689260;
TOTAL (The amounts shown do not include VAT)
2
Lot Title
E199 - ETANERCEPT [25 MG/ML; 1 ML; FRS]
Base Price
4 632,18

2.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
E199 ETANERCEPT [25 MG/ML; 1 ML; FRS] 84,000000 NXTWY.UMT.17649
Buyer Comment: 500162166 | Laboratórios Pfizer, Lda. | CPA:2023491/96/0511 | NºAIM:4163788;
TOTAL (The amounts shown do not include VAT)
3
Lot Title
L1066 - LENVATINIB [10 MG; CÁP/ COMP]
Base Price
16 500,00

3.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
L1066 LENVATINIB [10 MG; CÁP/ COMP] 300,000000 NXTWY.UMT.17649
Buyer Comment: 507847660 | EF - Eisai Farmacêutica, Unipessoal, Lda. | CPA:2023491/493/0418 | NºAIM:5654769;
TOTAL (The amounts shown do not include VAT)
4
Lot Title
S349 - SUNITINIB [25 MG; CÁP/COMP]
Base Price
40 577,04

4.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
S349 SUNITINIB [25 MG; CÁP/COMP] 672,000000 NXTWY.UMT.17649
Buyer Comment: 500162166 | Laboratórios Pfizer, Lda. | CPA:2023491/96/0523 | NºAIM:5072079; 501505334 | Farmoz - Soc. Técnico Medicinal, S.A. | CPA:2023491/46/0671 | NºAIM:5840301; 502248793 | Mylan, Lda. | CPA:2023491/120/0697 | NºAIM:5770136; 508622263 | Accord Healthcare, Unipessoal, Lda. | CPA:2023491/528/0608 | NºAIM:5818521;
TOTAL (The amounts shown do not include VAT)
5
Lot Title
T1636 - TILDRACIZUMAB [100 MG/ 1 ML; SOL INJ; SERINGA]
Base Price
475 000,00

5.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
T1636 TILDRACIZUMAB [100 MG/ 1 ML; SOL INJ; SERINGA] 250,000000 NXTWY.UMT.17649
Buyer Comment: 503538108 | Logista, Transportes, Transitários e Pharma, Unipessoal, Lda. | CPA:2023491/1001/0019 | NºAIM:5758677;
TOTAL (The amounts shown do not include VAT)

Evaluation

Evaluation
Vision

Avaliação

Definir modelo de avaliação
Modalidade de avaliação
Método de Avaliação
Divulgar critérios de avaliação

Critérios da Avaliação

1 - B369 - BLEOMICINA (PÓ P/ SOL INJ) [15.000 U.I.; FRS]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PreçoPreço100%

Normas de desempate

2 - E199 - ETANERCEPT [25 MG/ML; 1 ML; FRS]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PreçoPreço100%

Normas de desempate

3 - L1066 - LENVATINIB [10 MG; CÁP/ COMP]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PreçoPreço100%

Normas de desempate

4 - S349 - SUNITINIB [25 MG; CÁP/COMP]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PreçoPreço100%

Normas de desempate

5 - T1636 - TILDRACIZUMAB [100 MG/ 1 ML; SOL INJ; SERINGA]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.PreçoPreço100%

Normas de desempate

Public Messages

Public Messages
TypeReferenceSubjectDate
No items found...